Shenzhen Salubris Pharmaceuticals Co., Ltd.
002294
Helyezés a részvények között
#3418
Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris... Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris Pharmaceuticals Co., Ltd. operates across the entire pharmaceutical value chain, from research and development to manufacturing and sales. The company primarily focuses on critical therapeutic areas within China, including cardiovascular, anti-diabetic, anti-cancer, and orthopedic medicine. Its diverse product portfolio features a variety of cardiovascular and cerebrovascular medications, such as allisartan isoproxil and clopidogrel bisulfate tablets, alongside injectable options like bivalirudin. A significant offering is the recombinant SeV-hFGF2/dF Injection, specifically developed for the treatment of diabetic foot disease. Salubris also manufactures anti-tumor and orthopedic drugs. Furthermore, its anti-infective range encompasses numerous injectable antibiotics, including ceftazidime and ceftriaxone sodium, as well as oral preparations such as azithromycin dispersible and levetiracetam tablets. The firm also innovates in biotechnological drugs, developing recombinant proteins and monoclonal antibodies. Complementing its domestic operations, Shenzhen Salubris Pharmaceuticals engages in the import, in-licensing, and out-licensing of medicines, particularly for European markets.
Részvényárfolyam
$4.48
Piaci kapitalizáció
$4.99B
Változás (1 nap)
-5.20%
Változás (1 év)
-41.89%
Ország
CN
Kereskedés Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)
Kategória
Healthcare
Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294) P/S aránya
P/S arány ekkor: October 2026 TTM: 7.09
Shenzhen Salubris Pharmaceuticals Co., Ltd. legfrissebb pénzügyi jelentései és részvényára alapján a vállalat jelenlegi árbevétel aránya (P/S, TTM) 7.09. 2024 végén ez az arány 8.59 volt.
P/S arány története a(z) Shenzhen Salubris Pharmaceuticals Co., Ltd. esetén 2006 és 2026 között
P/S arány az év végén
| Év | P/S arány | Változtassa meg |
|---|---|---|
| 2026 (TTM) | 7.09 | -44.73% |
| 2025 | 12.83 | 49.35% |
| 2024 | 8.59 | -20.58% |
| 2023 | 10.81 | 4.34% |
| 2022 | 10.36 | 8.68% |
| 2021 | 9.54 | -10.38% |
| 2020 | 10.64 | 128.80% |
| 2019 | 4.65 | 6.64% |
| 2018 | 4.36 | -57.85% |
| 2017 | 10.35 | 29.67% |
| 2016 | 7.98 | -11.93% |
| 2015 | 9.06 | 13.07% |
| 2014 | 8.01 | -17.09% |
| 2013 | 9.66 | 5.70% |
| 2012 | 9.14 | 53.31% |
| 2011 | 5.96 | -52.70% |
| 2010 | 12.61 | 30.91% |
| 2009 | 9.63 | -9.70% |
| 2008 | 10.67 | -33.95% |
| 2007 | 16.15 | -30.69% |
| 2006 | 23.30 | 0.00% |
P/S arány hasonló vállalatoknál vagy versenytársaknál
| Vállalat | P/S arány | P/S arány különbség | Ország |
|---|---|---|---|
| 13.24 | 86.77% |
US
|
|
| 2.74 | -61.33% |
FR
|
|
| 8.98 | 26.59% |
JP
|
|
| 2.54 | -64.18% |
US
|
|
| 3.02 | -57.47% |
CH
|
